Xelpros is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 2 US drug patents filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 12, 2029. Details of Xelpros's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9629852 | Ophthalmic composition comprising a prostaglandin |
Sep, 2029
(2 years from now) | Active |
| US9539262 | Ophthalmic composition comprising a prostaglandin |
Oct, 2028
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Xelpros's patents.
Latest Legal Activities on Xelpros's Patents
Given below is the list of recent legal activities going on the following patents of Xelpros.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Oct, 2024 | US9629852 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9539262 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Oct, 2020 | US9629852 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jul, 2020 | US9539262 |
| Recordation of Patent Grant Mailed
Critical | 25 Apr, 2017 | US9629852 |
| Patent Issue Date Used in PTA Calculation
Critical | 25 Apr, 2017 | US9629852 |
| Email Notification
Critical | 06 Apr, 2017 | US9629852 |
| Issue Notification Mailed
Critical | 05 Apr, 2017 | US9629852 |
| Dispatch to FDC | 17 Mar, 2017 | US9629852 |
| Application Is Considered Ready for Issue
Critical | 16 Mar, 2017 | US9629852 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets
invalidated somehow, the
generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal
pitfalls. Given
below are details of the litigation history of Xelpros and ongoing
litigations to
help you estimate the early arrival of Xelpros generic.
Xelpros's Litigations
Xelpros been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 06, 2013, against patent number US9629852. The petitioner , challenged the validity of this patent, with Ajay Jaysingh Khopade et al as the respondent. Click below to track the latest information on how companies are challenging Xelpros's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9629852 | June, 2013 |
Decision
(26 Apr, 2016) | Ajay Jaysingh Khopade et al | |
US patents provide insights into the exclusivity only within the United States, but
Xelpros is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Xelpros's family patents as well as insights into
ongoing legal events
on those patents.
Xelpros's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Xelpros:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) | University Hospital Dubrava | NA | COMPLETED
(Sep 1, 2026) | PHASE2, PHASE3 |
| Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension | PolyActiva Pty Ltd | NA | ACTIVE NOT RECRUITING
(Jul 1, 2026) | PHASE2 |
| Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension | Qlaris Bio, Inc. | NA | COMPLETED
(Jul 1, 2026) | PHASE2, PHASE3 |
| A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China | Santen Pharmaceutical Co., Ltd. | NA | ACTIVE NOT RECRUITING
(May 1, 2026) | PHASE3 |
| Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction | Alcon Research | NA | COMPLETED
(Apr 1, 2026) | PHASE3 |
Generic Launch
Generic Release Date:
Xelpros's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 12, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Xelpros Generic API suppliers:
Latanoprost is the generic name for the brand Xelpros. 12 different companies have already filed for the generic of Xelpros, with Apotex Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Xelpros's generic
Alternative Brands for Xelpros
Xelpros which is used for managing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension., has several other brand drugs using the same active ingredient (Latanoprost). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Latanoprost, Xelpros's active ingredient. Check the complete list of approved generic manufacturers for Xelpros
About Xelpros
Xelpros is a drug owned by Sun Pharmaceutical Industries Ltd. It is used for managing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Xelpros uses Latanoprost as an active ingredient. Xelpros was launched by Sun Pharma in 2018.
Approval Date:
Xelpros was approved by FDA for market use on 12 September, 2018.
Active Ingredient:
Xelpros uses Latanoprost as the active ingredient. Check out other Drugs and Companies using Latanoprost ingredient
Treatment:
Xelpros is used for managing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Dosage:
Xelpros is available in emulsion form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.005% | EMULSION | Discontinued | OPHTHALMIC |